Positive Interim Phase 2 Data for Artelo’s ART27.13 Drug
Interim data from the Phase 2 CAReS trial showed that patients titrated to the highest dose of ART27.13 (1,300...
New Phase 3 Data for CAN-2409 in Prostate Cancer at ASTRO
CAN-2409 improved disease-free survival by 30% versus placebo in a 745-patient Phase 3 trial in intermediate-to-high-risk localized prostate cancer...
Pioneering Pancreatic Cancer Trial Launched by Elicio, MSK
Updated Phase 1 data from Elicio’s AMPLIFY-201 program reported a 16.3-month median recurrence-free survival and 28.9-month median overall survival...
Clinuvel’s Novel Formulations Advance in Preclinical Program
CLINUVEL has advanced a portfolio of sustained‑release liquid depot formulations for peptides into preclinical testing, targeting predictable release kinetics...
Breakthrough: NIH Funds Alzheimer’s Drug AD04 with $2.5M
ADvantage Therapeutics secured a $2.5 million Phase II SBIR grant from the National Institute on Aging to advance AD04,...
Immuneering to Discuss Pancreatic Cancer Survival Data
Updated overall survival and safety data from a 34‑patient, first‑line pancreatic cancer cohort treated with atebimetinib plus modified gemcitabine/nab‑paclitaxel...
Groundbreaking Data: Revita Maintains Weight Loss Post-GLP-1
In a randomized, double-blind, sham-controlled midpoint cohort of REMAIN-1 (N=45), Revita produced an additional 2.5% total body weight loss...
Organogenesis Gives Update on Second Phase 3 Renu® Study
ReNu’s second Phase 3 randomized trial in symptomatic knee osteoarthritis missed its primary endpoint, showing a 0.5-point advantage over...
Cidara Doses Patients in Phase 3 Flu Prevention Trial
Cidara has begun dosing in ANCHOR, a global Phase 3 trial of CD388, a single 450 mg subcutaneous dose...
AbbVie’s Rinvoq: A Surging New Option for GCA Treatment
Forty percent of rheumatologists report initiating Rinvoq (upadacitinib) for giant cell arteritis (GCA) within weeks of approval, with nearly...